Hemodialysis | Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Hemodialysis research study

What is the primary objective of this study?

The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Who is eligible to participate?

Inclusion Criteria: chronic hemodialysys (> 3 months) anuria (diuresis <200 mL/day) - Exclusion Criteria: Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Spironolactone (drug)

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status

Unknown status

Start Date:

Completed Date:

Phase: Phase 4

Type: Interventional


Primary Outcome:

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Luis F Michea, MD PhD

Lead Sponsor: Universidad Los Andes


More information:

Michea L, Vukusich A, González M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004 Oct;66(4):1647-53.

Discuss Spironolactone